Chronic limb-threatening ischemia (CLTI) carries a significant risk of limb loss and thus demands urgent attention. Calcified atherosclerotic disease affecting the infra-popliteal (IP) arteries poses a formidable challenge for effective revascularization due to the narrow vessel diameter and the common presence of extensively calcified, long occlusive lesions. Intravascular lithotripsy (IVL) is an endovascular treatment that induces microfractures in the medial calcifications of blood vessels, thereby facilitating the clearance of calcified obstructive arterial lesions. This review assesses the growing body of evidence from multiple prospective studies that have investigated the role of IVL in the treatment of peripheral arterial disease (PAD) involving the IP segment. The clinical efficacy of IVL has been extensively studied and validated in various trials and real-world experiences. These studies consistently demonstrate IVL's ability to achieve vessel preparation, with excellent procedural success rates and low rates of major adverse events. Moreover, IVL has shown remarkable versatility, proving effective across a wide spectrum of PAD, including iliac artery disease, femoropopliteal disease and IP calcified disease. The available results from existing literature are encouraging and demonstrates safety and efficacy of the technology in treating calcified PAD. Additional studies on a larger scale are needed to better understand its long-term effects.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.23736/S0021-9509.24.13148-5 | DOI Listing |
Am Heart J
December 2024
Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Technische Universität München; DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany.
Background: Percutaneous coronary intervention of severely calcified lesions is limited by inadequate stent expansion and poor clinical outcomes. Over the past decade, several devices and techniques have been developed for calcium modification and lesion preparation. Intravascular lithotripsy (IVL) is a novel tool in this context.
View Article and Find Full Text PDFFront Cardiovasc Med
November 2024
Department of Cardiology, Hospital of the Brothers of Mercy Trier, Trier, Germany.
Background: Treating heavily calcified vessels is a challenging task in patients with an impaired left ventricular ejection fraction. Percutaneous mechanical circulatory support (pMCS) is increasingly used in patients in high-risk percutaneous coronary intervention (HRPCI).
Methods: In this retrospective registry, we investigated 25 patients undergoing a protected HRPCI receiving either intravascular lithotripsy (IVL + pMCS; = 11) or rotational atherectomy (RA + pMCS; = 14).
Can J Cardiol
December 2024
GMV Care & Research, Maria Cecilia Hospital, Cotignola, Italy.
Mitral annular calcification (MAC) is a chronic degenerative process linked to increased cardiovascular disease and mortality. In patients with degenerative mitral stenosis (DMS), management is typically pharmacological until severe symptoms arise, with surgery often deemed too high-risk. Balloon valvuloplasty has never been a viable option due to the extensive mitral calcifications of DMS anatomies; however, lithotripsy-assisted percutaneous mitral commissurotomy recently emerged as a new alternative for surgery-ineligible patients.
View Article and Find Full Text PDFAnn Vasc Surg
December 2024
Vascular and Endovascular Surgery Department. Cabueñes University Hospital, Gijón, Spain.
Objective: The aim of this study is to assess the safety and feasibility of intravascular lithotripsy (IVL) for the treatment of common femoral artery (CFA).
Methods: We analyzed patients who received IVL treatment for CFA from September 2021 to April 2023. All patients included presented with chronic limb threatening ischemia (CLTI).
Prog Cardiovasc Dis
December 2024
The Christ Hospital Heart & Vascular Institute and The Carl and Edyth Lindner Center for Research and Education, Cincinnati, Ohio, USA.. Electronic address:
The presence and severity of calcified coronary plaque negatively impacts angiographic and clinical outcomes following percutaneous coronary intervention (PCI). Severe coronary calcification is associated with suboptimal stent delivery, deployment, apposition and expansion which can lead to in-stent restenosis and/or thrombosis. Severe coronary calcification is associated with incremental hazard for adverse clinical events, including death, during 5-10 years following PCI despite the use of new generation drug- eluting stents.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!